TEP-TDM au 68Ga-FAPI-46
Phase 2Radiopharmaceutical
TEP-TDM au 68Ga-FAPI-46 is one of 16 small molecule programs targeting Biliary Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Biliary Cancer
#DrugCompanyPhaseTrials
1Herceptin
RochePhase 3
Zaniducla
Jazz PharmaceuticalsPhase 3
Braftovi
PfizerPhase 3
Mektovi
PfizerPhase 3
Lytgobi
Taiho Oncology, Inc.Phase 3
Tibsovo
SServier
Phase 3
Nerlynx
PPuma Biotechnology, Inc.
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Gemzar
Johnson & JohnsonPhase 2
Rubraca
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TEP-TDM au 68Ga-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Bordeaux